<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084032</url>
  </required_header>
  <id_info>
    <org_study_id>AIEDRP AIN502</org_study_id>
    <nct_id>NCT00084032</nct_id>
  </id_info>
  <brief_title>Anti-HIV Medications and Structured Treatment Interruptions for People Recently Infected With HIV</brief_title>
  <official_title>A Randomized, Multicenter Trial to Determine Whether Induction Therapy Followed by Treatment Interruption is Superior to Induction Therapy Alone in the Treatment of Primary HIV Infection (PHI): The Structured Treatment Interruption (STI) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      People recently infected with HIV who are treated with anti-HIV medications may develop
      strong immune system responses to HIV and may be able to control the virus without continuing
      to take these medications. The purpose of this study is to see if giving anti-HIV medications
      to people soon after they have been infected with HIV can help them control HIV. The study
      will also see if the immune system can control the amount of HIV virus in the blood (viral
      load) even after a person has stopped taking the medications. The study will evaluate three
      different schedules of stopping and starting anti-HIV medications to see which schedule is
      best able to boost a patient's immune system to control HIV viral load.

      Hypothesis: Combination therapy started in primary HIV infection, in conjunction with
      structured treatment interruptions, will result in greater control of viremia off treatment
      than induction therapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initiation of treatment during acute HIV infection seems to result in greater suppression of
      viral replication than noted during chronic infection and better recovery of certain CD4
      subpopulations. However, it is difficult for patients treated during acute infection to
      maintain long-term continuous antiretroviral (ARV) treatment because of difficulty adhering
      to complicated medication regimens, drug-related toxicities, and cost of medications. Acutely
      infected patients who have undergone early initiation of treatment followed by structured
      treatment interruptions (STIs) appear to have lower off-treatment viral loads than historical
      controls. This study will evaluate whether effective ARV treatment during acute and early HIV
      infection followed by STI will result in lower viral setpoints than would otherwise be
      expected.

      This trial will have 2 steps and will last for a maximum of 104 weeks. Participants will
      either enter Step 1 and continue on to Step 2 or enter Step 2 directly. During Step 1,
      participants with acute or early HIV infection will be given 24 weeks of ARV therapy.
      Participants may take any combination of FDA-approved ARV medications that they and their
      doctors select. Participants will have study visits at study entry and Weeks 1, 4, 8, and 20.
      After 24 weeks on Step 1, participants may enroll in Step 2.

      Participants in Step 1 and people with early or acute HIV infection who began ARV treatment
      within 21 days of diagnosis and have had no more than 1 year of treatment may enroll in Step
      2. During Step 2, participants will be randomly assigned to one of two study arms:

        -  Arm 1: Participants will continue taking ARV therapy for 16 weeks and then stop ARVs for
           64 weeks.

        -  Arm 2: Participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4
           weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.

      Participants in both study arms will restart ARVs regardless of STI duration if their viral
      load is above 50,000 copies/ml, they progress to CDC category C disease, or their CD4 count
      falls below 350 cells/mm3 or declines more than 50% from the last on-treatment CD4 level.

      Step 2 will last 80 weeks. For the first year, participants will have study visits every 1 to
      4 weeks, depending on whether they are taking ARVs. During the second year, participants will
      have study visits every 8 weeks. Study visits will include a brief medical history, blood and
      pregnancy tests, and voluntary behavioral questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean HIV viral load between arms</measure>
    <time_frame>At Week 80</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Structured treatment interruption</intervention_name>
    <description>Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral regimen</intervention_name>
    <description>Participants will take any combination of FDA-approved ARV medications prescribed by their physician</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: Step 2, Arm 3 has been eliminated as of 12/13/04.

        Inclusion Criteria for Step 1:

          -  Acute or early HIV infection as defined by the study

          -  Agrees to use acceptable methods of contraception

          -  Agrees to begin antiretroviral treatment regimen within 21 days of diagnosis and no
             more than 3 days after study entry

        Exclusion Criteria for Step 1:

          -  Unwilling to follow random assignment in Step 2

          -  Abnormal laboratory result within 21 days prior to study entry, unless abnormality is
             considered part of acute HIV infection

          -  Have taken antiretroviral drugs other than for postexposure prophylaxis (PEP).
             Patients who have undergone up to 30 days of previous PEP treatment are not excluded.

          -  Pregnancy or breastfeeding

          -  Previous participation in an HIV vaccine trial

          -  Previous use of experimental therapeutic immunizations or cytokine infusions

        Inclusion Criteria for Participants Enrolling Directly into Step 2:

          -  Viral load of less than 400 copies/ml

          -  Enrolled in the AIEDRP CORE01 study, with stored blood samples obtained within 21 days
             prior to starting treatment on CORE01

          -  Currently receiving antiretroviral treatment regimen, with no interruptions for more
             than 7 consecutive days since the beginning of treatment

          -  Antiretroviral treatment was started within 21 days after HIV diagnosis

          -  Agrees to use acceptable methods of contraception

        Exclusion Criteria for Step 2:

          -  Unwilling to follow random assignment to study arms and follow scheduled treatment
             interruptions

          -  More than 52 weeks of ARV treatment since diagnosis of acute/early HIV infection prior
             to entering Step 2

          -  CD4 count less than 350 cells/mm3 within 28 days of entry into Step 2

          -  AIDS-defining illness

          -  Pregnant or breastfeeding

          -  Previous participation in an HIV vaccine trial

          -  Previous use of experimental therapeutic immunizations or cytokine infusions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Rosenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Don Smith, MB, ChB, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New South Wales, Australia</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.gov/ct/show/NCT00086372</url>
    <description>Click here for more information on AIEDRP CORE01</description>
  </link>
  <reference>
    <citation>Girard PM, Schneider V, Deh√©e A, Mariot P, Jacomet C, Delphin N, Damond F, Carcelain G, Autran B, Saimot AG, Nicolas JC, Rozenbaum W. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS. 2001 Jan 26;15(2):275-7.</citation>
    <PMID>11216939</PMID>
  </reference>
  <reference>
    <citation>Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, Carr A, Cooper DA. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS. 2000 Dec 1;14(17):2643-51.</citation>
    <PMID>11125882</PMID>
  </reference>
  <reference>
    <citation>Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000 Jan;181(1):121-31.</citation>
    <PMID>10608758</PMID>
  </reference>
  <reference>
    <citation>Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vanderhoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002 Sep 1;186(5):634-43. Epub 2002 Aug 9.</citation>
    <PMID>12195350</PMID>
  </reference>
  <reference>
    <citation>Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):27-37.</citation>
    <PMID>12352147</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2004</study_first_submitted>
  <study_first_submitted_qc>June 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2004</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Infection</keyword>
  <keyword>Treatment Interruption</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>Primary HIV Infection</keyword>
  <keyword>PHI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

